SKOV-3 human ovarian carcinoma cells (ATCC, Manassas, VA, USA) were grown in McCoy's medium (Biochrom; Merck KGaA, Darmstadt, Germany) supplemented with 10% foetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA), 2 mM L-glutamine (Biochrom; Merck KGaA), 100 U/ml penicillin and 100 µg/ml streptomycin (Biochrom; Merck KGaA). SKBR-3 cells (ATCC) were cultured in the same medium but with 20% foetal bovine serum.
Skov 3 human ovarian carcinoma cells
Manufactured by American Type Culture Collection
Sourced in United States
SKOV-3 is a human ovarian carcinoma cell line derived from the ascites of a patient with a papillary cystadenocarcinoma of the ovary. The cells exhibit an epithelial morphology and are characterized as a model for ovarian cancer research.
Automatically generated - may contain errors
Lab products found in correlation
Streptomycin, by Merck Group (1 mentions)
Penicillin, by Merck Group (1 mentions)
L glutamine, by Merck Group (1 mentions)
Foetal bovine serum (fbs), by Merck Group (1 mentions)
Foetal bovine serum (fbs), by American Type Culture Collection (1 mentions)
Sk br 3 cells, by American Type Culture Collection (1 mentions)
Matrigel, by BD (1 mentions)
Hanks balanced salt solution (hbss), by Thermo Fisher Scientific (1 mentions)
2 protocols using skov 3 human ovarian carcinoma cells
1
Culturing Human Ovarian Carcinoma and Breast Cancer Cells
2
Radioimmunoconjugate Evaluation in Ovarian Cancer Xenografts
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All experiments were performed in compliance with licences issued under the UK Animals (Scientific Procedures) Act 1986 following local ethical review and the United Kingdom National Cancer Research Institute Guidelines for Animal Welfare in Cancer Research [4 (link)]. Six female CD-1 nude mice (6–8-week-old) were injected subcutaneously on the flank with high HER2-overexpressing SK-OV-3 human ovarian carcinoma cells (5 × 106/mouse) (ATCC, USA) suspended in 30% Matrigel (BD Biosciences, UK) diluted in HBSS (Gibco, Thermo Scientific, UK). Tumours were allowed to grow for 3–4 weeks and the radioimmunoconjugates, diluted in saline, were injected via the tail vein (activity range 5.58–8.52 MBq/mouse, quantity of antibody range 8–25 μg) (see Table 1 ).
Radioimmonucongugate, level of activity (Ainj) and quantity of antibody (mAbinj) injected for the six mice included in the study
| Mouse no. | Radioimmonoconjugate | Ainj (MBq) | mAbinj (μg) |
|---|---|---|---|
| M1 | 111In-DTPA-trastuzumab | 6.14 | 12 |
| M2 | 111In-DTPA-ICR12 | 6.39 | 12 |
| M3 | 111In-DTPA-ICR12 | 5.58 | 10 |
| M4 | 111In-DOTA-trastuzumab | 8.52 | 25 |
| M5 | 111In-DOTA-trastuzumab | 8.32 | 8 |
| M6 | 111In-DTPA-ICR12 | 7.16 | 10 |
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!